ArticleClinical pharmacokinetics2021

Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease.

Yan Xin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.